年内已诞生3只主动权益“翻倍基” 全部来自创新药

Group 1 - The core viewpoint of the article highlights the growing investment interest in the innovative pharmaceutical sector, which has led to the emergence of three actively managed equity funds that have doubled their returns this year [1] - The fund "Changcheng Medical Industry Selection" leads the year-to-date performance among actively managed equity funds with a return of 119.66% [1] - Other funds, "Yongying Medical Innovation Smart Selection" and "Bank of China Hong Kong Stock Connect Medical," have also shown impressive returns of 106.37% and 105.43% respectively [1]